The DKK1 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the 786-O clear cell renal cell carcinoma (ccRCC) line, featuring targeted disruption of the secreted Wnt antagonist DKK1. By ablating DKK1-mediated inhibition, these cells enable dissection of canonical Wnt/??-catenin signaling and its downstream effects in a VHL-mutant tumor context. The polyclonal population preserves editing heterogeneity, providing a robust loss-of-function model for functional studies.
The 786-O cell line was established from a primary clear cell renal adenocarcinoma and is a widely used model of ccRCC, characterized by a VHL tumor suppressor mutation that causes constitutive stabilization of hypoxia-inducible factor (HIF) transcription factors. This VHL-deficient background replicates the molecular pathology of most sporadic ccRCC cases, making the cells particularly relevant for studying HIF-driven oncogenic programs and tumor-specific signaling. The addition of a DKK1 knockout allows investigation of crosstalk between Wnt pathway regulation and the aberrant hypoxia signaling typical of this cancer type.
DKK1 is a secreted inhibitor that binds LRP5/6 co-receptors and Kremen proteins (KREMEN1/2), promoting internalization and degradation of the Wnt receptor complex. Its absence permits Wnt ligands such as Wnt1 and Wnt3a to activate Frizzled receptors, leading to Dvl-mediated inhibition of GSK3??, ??-catenin stabilization, and TCF/LEF-dependent transcription of targets like MYC, CCND1, and AXIN2. DKK1 expression is regulated by inputs including p53, ??-catenin/TCF, TGF-??1/Smad, HIF-1??, and c-Myc, creating feedback and crosstalk that modulate pathway output. Knockout also impacts non-canonical Wnt/JNK signaling and expression of osteogenic markers (RUNX2, ALPL), relevant to bone metastasis.
In the 786-O ccRCC context, VHL loss stabilizes HIF-1??, which transcriptionally upregulates DKK1, thereby suppressing Wnt signaling. DKK1 knockout relieves this suppression, potentially enhancing ??-catenin-dependent proliferation and survival and contributing to tumor progression, metastasis, and therapy resistance. This model thus allows dissection of how Wnt pathway reactivation cooperates with VHL deficiency in ccRCC. Additionally, given DKK1??s role in bone biology, these cells facilitate studies of molecular mechanisms underlying bone metastasis, including altered osteogenic marker expression.
The DKK1 knockout polyclonal cells are suited for investigating Wnt/??-catenin and non-canonical Wnt signaling in ccRCC, tumor cell proliferation, migration, invasion, and drug resistance. Researchers can employ standardized assays such as TOPFlash/TCF reporter, qRT-PCR for Wnt targets (AXIN2, MYC, CCND1), Western blot for ??-catenin, MTT/BrdU proliferation, Annexin V apoptosis, and migration/invasion tests. They are also compatible with RNA-seq transcriptomic profiling and high-throughput screening for Wnt pathway modulators. For further technical information, please contact Ascent Research.
